Nevertheless, the undisputed role of orexin in wakefulness led to the development of dual orexin receptor antagonists (DORAs), a new class of sedatives which includes FDA‐approved Suvorexant, Lemborexant and Daridorexant (in Europe and UK too) for the treatment of insomnia (Merck Sharp and Dohme Corp 2014; Idorsia Pharmaceuticals US Inc 2022; Eisai R&D Management Co. Ltd 2019). Here, HCRT is linked to insomnia.